Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome
Background: Metabolic syndrome (MetSyn) is a disease cluster causing cardiovascular disease, cancer, and high mortality. Metformin is the most common antidiabetic agent inhibiting the tumorigenesis and insulin resistance of MetSyn. We describe the association between metformin intake and survival of...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Preventive Medicine Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211335524003437 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846138545226383360 |
|---|---|
| author | Ji Soo Park Soo Jin Moon Hyung Seok Park Sang-Hoon Cho |
| author_facet | Ji Soo Park Soo Jin Moon Hyung Seok Park Sang-Hoon Cho |
| author_sort | Ji Soo Park |
| collection | DOAJ |
| description | Background: Metabolic syndrome (MetSyn) is a disease cluster causing cardiovascular disease, cancer, and high mortality. Metformin is the most common antidiabetic agent inhibiting the tumorigenesis and insulin resistance of MetSyn. We describe the association between metformin intake and survival of patients with type 2 diabetes mellitus (T2DM) and MetSyn, according to the presence of cancer. Methods: We analyzed the clinical characteristics and all-cause mortality of patients with T2DM and MetSyn using a 5-year dataset between January 1, 2009 and December 31, 2013 derived from the Korean National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS). Cox proportional hazards regression models were used to investigate metformin effects adjusted for other potential confounding variables. Results: Among a total of 43,043 patients with both MetSyn and T2DM, 24,725 patients (57.4 %) received metformin regularly. Female sex, high income, regular exercise, and metformin use were good prognostic factors, whereas hypertension, current smoking, cancer, and diabetes medication (except metformin) were poor prognostic factors. After adjustment for possible confounding variables, metformin showed a significant effect on patient survival (hazard ratio [HR], 0.68; 95 % confidence interval [CI], 0.63–0.75; p < 0.001). The effect of metformin was pronounced on the group of patients with liver, lung, colorectal, or prostate cancers (HR, 0.57; CI, 0.46–0.70). Conclusions: Metformin intake may be related to favorable survival among patients with T2DM and MetSyn. The efficacy might be more remarkable in those with liver, lung, colorectal, and prostate cancers. The potential benefit of metformin in patients with these risk factors should be further investigated. |
| format | Article |
| id | doaj-art-9af3f94993874f56bfac5a2d8ef7a51a |
| institution | Kabale University |
| issn | 2211-3355 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Preventive Medicine Reports |
| spelling | doaj-art-9af3f94993874f56bfac5a2d8ef7a51a2024-12-07T08:26:14ZengElsevierPreventive Medicine Reports2211-33552024-12-0148102928Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndromeJi Soo Park0Soo Jin Moon1Hyung Seok Park2Sang-Hoon Cho3Cancer Prevention Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Department of Medicine, Yonsei University College of Medicine, Seoul, Republic of KoreaDepartment of Statistics and Actuarial Science, Soongsil University, South KoreaCancer Prevention Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea; Corresponding authors at: Department of Statistics and Actuarial Science, Soongsil University, 369 Sangdo-ro, Dongjak-gu, Seoul 06978, Republic of Korea (Sang-Hoon Cho). Department of Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea (Hyung Seok Park).Department of Statistics and Actuarial Science, Soongsil University, South Korea; Corresponding authors at: Department of Statistics and Actuarial Science, Soongsil University, 369 Sangdo-ro, Dongjak-gu, Seoul 06978, Republic of Korea (Sang-Hoon Cho). Department of Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea (Hyung Seok Park).Background: Metabolic syndrome (MetSyn) is a disease cluster causing cardiovascular disease, cancer, and high mortality. Metformin is the most common antidiabetic agent inhibiting the tumorigenesis and insulin resistance of MetSyn. We describe the association between metformin intake and survival of patients with type 2 diabetes mellitus (T2DM) and MetSyn, according to the presence of cancer. Methods: We analyzed the clinical characteristics and all-cause mortality of patients with T2DM and MetSyn using a 5-year dataset between January 1, 2009 and December 31, 2013 derived from the Korean National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS). Cox proportional hazards regression models were used to investigate metformin effects adjusted for other potential confounding variables. Results: Among a total of 43,043 patients with both MetSyn and T2DM, 24,725 patients (57.4 %) received metformin regularly. Female sex, high income, regular exercise, and metformin use were good prognostic factors, whereas hypertension, current smoking, cancer, and diabetes medication (except metformin) were poor prognostic factors. After adjustment for possible confounding variables, metformin showed a significant effect on patient survival (hazard ratio [HR], 0.68; 95 % confidence interval [CI], 0.63–0.75; p < 0.001). The effect of metformin was pronounced on the group of patients with liver, lung, colorectal, or prostate cancers (HR, 0.57; CI, 0.46–0.70). Conclusions: Metformin intake may be related to favorable survival among patients with T2DM and MetSyn. The efficacy might be more remarkable in those with liver, lung, colorectal, and prostate cancers. The potential benefit of metformin in patients with these risk factors should be further investigated.http://www.sciencedirect.com/science/article/pii/S2211335524003437MetforminMetabolic syndromeDiabetesCancerMortality |
| spellingShingle | Ji Soo Park Soo Jin Moon Hyung Seok Park Sang-Hoon Cho Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome Preventive Medicine Reports Metformin Metabolic syndrome Diabetes Cancer Mortality |
| title | Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome |
| title_full | Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome |
| title_fullStr | Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome |
| title_full_unstemmed | Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome |
| title_short | Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome |
| title_sort | survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome |
| topic | Metformin Metabolic syndrome Diabetes Cancer Mortality |
| url | http://www.sciencedirect.com/science/article/pii/S2211335524003437 |
| work_keys_str_mv | AT jisoopark survivalbenefitofmetforminuseaccordingtocancerdiagnosisindiabeticpatientswithmetabolicsyndrome AT soojinmoon survivalbenefitofmetforminuseaccordingtocancerdiagnosisindiabeticpatientswithmetabolicsyndrome AT hyungseokpark survivalbenefitofmetforminuseaccordingtocancerdiagnosisindiabeticpatientswithmetabolicsyndrome AT sanghooncho survivalbenefitofmetforminuseaccordingtocancerdiagnosisindiabeticpatientswithmetabolicsyndrome |